WilmerHale Counsels Vividion in Strategic Research Collaboration with Celgene

WilmerHale Counsels Vividion in Strategic Research Collaboration with Celgene

Firm News

Vividion Therapeutics, a biotechnology company using novel proteomics and chemistry platforms, has announced that it entered into a strategic research collaboration with Celgene Corporation and will receive $101 million in upfront and equity consideration. The multi-year collaboration will focus on the identification and development of small molecules that function through the ubiquitin proteasome system, modulating specific protein levels for therapeutic benefit, against targets for a range of oncology, neurodegenerative and inflammatory indications.

The WilmerHale deal team counseling Vividion included Steven Singer, Steven Barrett and Mat Trachok.

Read Vividion Therapeutics' press release for more information.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.